Objective: Report of a case of Multisystem Inflammatory Syndrome in Children (MIS-C) post-COVID 19 and review of articles on the topic. Results: Coronavirus 2 (SARS-CoV-2) infection is a disease whose symptoms are similar between the adult and pediatric population, ranging from asymptomatic cases to more serious conditions that have spread global terror due to the high number of infections worldwide deaths. However, children have presented a milder clinic. It is worth mentioning, however, that this population is not completely risk-free, with reports of the association of the Coronavirus triggering inflammatory diseases, such as the so-called MIS-C whose complications can be as serious as the forms of symptoms experienced by adults. Conclusion: The temporal and serological relationship of a link with SARS-CoV-2 infection is supported by consistent data, however further studies are needed to establish SARS-CoV-2 as an inciting agent. Due to the severity of MIS-C, knowledge about this disease is necessary for a quick diagnosis and early treatment, aiming to reduce systemic lesions. Due to the increase in the number of cases of children affected by MIS-C, the use of immunomodulatory drugs, such as intravenous immunoglobulin (IVIG), aspirin, and systemic glucocorticoids, has been instituted as first-line therapy, to reduce inflammation and late complications.
- Uddin Md Bashir et al. Ancestral origin, antigenic resemblance and epidemiological insights of novel coronavirus (SARS-CoV-2): Global burden and Bangladesh perspective. Infection, GeneticsandEvolution, 2020, v. 84, p. 104440.
- Farias ECF, Justino MCA, Mello MLFMF. Multisystem Inflammatory Syndrome in a child associated with Coronavirus Disease 19 in the brazilian amazon: fatal outcome in an infant. Rev. paul. Pediatr., São Paulo, 2020, v. 38.
- Dos Santos WG. Natural history of COVID-19 and current knowledge on treatment therapeutic options. Biomedicine & Pharmacotherapy, 2020, p. 110493.
- Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death. 2020.
- Diorio C et al. Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS–CoV-2. The Journal of clinical investigation, 2020, v. 130, n. 11.
- Pereira MFB et al. Severe clinical spectrum with high mortality in pediatric patients with COVID-19 and multisystem inflammatory syndrome. Clinics, 2020, v. 75.
- Williams PCM et al. SARS-CoV-2 in children: spectrum of disease, transmission and immunopathological underpinnings. Pathology, 2020.
- Galeotti C, Bayry J. Autoimmune and inflammatory diseases following COVID-19. NatureReviewsRheumatology, 2020, p. 1-2.
- Kaushik A et al. A Systematic Review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 Infection. The Pediatric infectious disease journal, 2020, v. 39, n. 11, p. e340-e346.
- Sarzaeim M, Rezaei N. Kawasaki Disease and Multisystem Inflammatory Syndrome in Children with COVID-19. SN comprehensiveclinical medicine, 2020, p. 1-6.
- Nakra NA. et al. Multisystem inflammatory syndrome in children (MIS-C) following SARS-CoV-2 infection: review of clinical presentation, hypothetical pathogenesis, and proposed management. Children, 2020, v. 7, n. 7, p. 69.
- Feldstein LR. et al. Multisystem inflammatory syndrome in US children and adolescents. New England Journal of Medicine, 2020, v. 383, n. 4, p. 334-346.
- Panupattanapong S, Brooks EB. New spectrum of COVID-19 manifestations in children: Kawasaki-like syndrome and hyperinflammatory response. Cleveland Clinic Journal of Medicine, 2020.
- Xu S, Chen M, Weng J. COVID-19 and Kawasaki disease in children. Pharmacological Research, 2020, v. 159, p. 104951.
- Chang Tu-Hsuan, Wu Jhong-Lin, Chang Luan-Yin. Clinical characteristics and diagnostic challenges of pediatric COVID-19: A systematic review and meta-analysis. JournaloftheFormosan Medical Association, 2020
- Chakraborty C. et al. SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options. Eur Rev Med Pharmacol Sci, 2020, v. 24, n. 7, p. 4016-4026.
- Walker DM, Tolentino VR. COVID-19: The impact on pediatric emergency care. Pediatric emergency medicine practice, 2020, v. 17, n. Suppl 6-1, p. 1-27.
- Feldstein LR, Tenforde MW, Friedman KG, Newhams M, Rose EB, Dapul H, Soma VL, Maddux AB, Mourani PM, Bowens C, Maamari M, Hall MW, Riggs BJ, Giuliano JS Jr, Singh AR, Li S, Kong M, Schuster JE, McLaughlin GE, Schwartz SP, Walker TC, Loftis LL, Hobbs CV, Halasa NB, Doymaz S, Babbitt CJ, Hume JR, Gertz SJ, Irby K, Clouser KN, Cvijanovich NZ, Bradford TT, Smith LS, Heidemann SM, Zackai SP, Wellnitz K, Nofziger RA, Horwitz SM, Carroll RW, Rowan CM, Tarquinio KM, Mack EH, Fitzgerald JC, Coates BM, Jackson AM, Young CC, Son MBF, Patel MM, Newburger JW, Randolph AG; Overcoming COVID-19 Investigators. Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19. JAMA. 2021 Mar 16;325(11):1074-1087. doi: 10.1001/jama.2021.2091.